Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA to spend $2.5 billion on IT modernisation

This article was originally published in Scrip

Executive Summary

The US FDAwill award 10 contractors up to a total of $2.5 billion for information technology and data centre management services over the next 10 years. The agency says the contracts are the cornerstone of its IT modernisation programme encompassing data management, data warehousing, IT infrastructure and security. "This contract sets the stage for the FDA to have IT to acquire, analyse and act on data critical for import protection, food protection and medical product safety plans," FDA commissioner Dr Andrew von Eschenbach said. The FDA's IT infrastructure has been widely criticised as inadequate and outdated for the agency's functions, particularly its ability to oversee foreign drug manufacturers.

You may also be interested in...



US FDA Facility Compliance Actions Could Speed Up Despite Inspections Freeze

With inspectors no longer out in the field, they have more time to wrap up work on previously completed facility evaluations, attorney Howard Sklamberg says; inspections freeze could delay manufacturers’ abilities to bring facilities into compliance following adverse inspection findings, as well as agency reclassifications of facility status.

Individualized Therapeutics Could Get Boost From NIH Platform Gene Therapy Pilot

Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.

US FDA Offers More Advice On Mid-Trial Changes For Pandemic-Impacted Studies

A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.

Topics

UsernamePublicRestriction

Register

SC030711

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel